Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for nocturnal hypertension in chronic kidney disease
ChiCTR2400094810Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in nocturnal hypertension (NH) and chronic kidney disease (CKD) (2 arms), sponsored by The Third Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Change in mean nocturnal blood pressure from baseline and Change in estimated glomerular filtration rate (eGFR). Planned start Jan 2025; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
nocturnal hypertension (NH)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2400094810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094810.